A Phase I, open-label, multi-center exploratory safety and efficacy study with PSMA, SSTR2 and GRPR targeted radioligand therapy in metastatic neuroendocrine prostate cancer
CAAA617H12101
Phase 2 other active
Quick answer
A Phase I, open-label, multi-center exploratory safety and efficacy study with PSMA, SSTR2 and GRPR targeted radioligand therapy in metastatic neuroendocrine prostate cancer for Metastatic neuroendocrine prostate cancer is a Phase 2 program (other) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Ophthalmics Europe
- Indication
- Metastatic neuroendocrine prostate cancer
- Phase
- Phase 2
- Modality
- other
- Status
- active